NEW YORK (GenomeWeb News) – Gene Bridges said today that Osaka, Japan-based drug developer Takeda Pharmaceutical will use Gene Bridges’ recombination technology under a commercial license agreement through its Japanese distributor, Funakoshi.
 
Gene Bridges’ Red/ET recombination technology is used to generate target vectors or to modify E. coli chromosomes. The Red/ET technology allows for engineering of molecules, BACs, or the E. Coli chromosome.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.